Drug Profile
Research programme: RNAi therapeutics - Alnylam/Takeda
Latest Information Update: 28 Dec 2017
Price :
$50
*
At a glance
- Originator Alnylam Pharmaceuticals; Takeda
- Developer Alnylam Pharmaceuticals
- Class Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Metabolic disorders
Most Recent Events
- 28 Dec 2017 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 28 Dec 2017 No recent reports of development identified for research development in Metabolic-disorders in USA (Parenteral)
- 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals